Although in our study we cannot evaluate the rate of patients in whom the target LDL-C goals have been reached, the recent data also clearly show that, in most cases, only combination therapy with statins, ezetimibe, and PCSK9 inhibitors might be on target for most ASCVD patients [23,24]. Here, PCSK9 is linked to atherosclerosis.